CLOs on the Move

ConjuGon Inc

www.conjugon.com

 
ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.conjugon.com
  • University Research Park 505 S Rosa Rd Ste 29
    Madison, WI USA 53719
  • Phone: 608.441.2890

Executives

Name Title Contact Details

Similar Companies

Syntron Bioresearch

Syntron Bioresearch is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.

Xigo Nanotools

Xigo Nanotools is a Morganville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.